Alison Quinn's Respiro Diagnostics raises GBP 1M for breath-based lung diagnostics
The UK company plans a September 2026 lung cancer clinical study after early proof-of-concept work in mesothelioma patients.
By Ryan Merket · Published

The UK company plans a September 2026 lung cancer clinical study after early proof-of-concept work in mesothelioma patients.